Clinigen Group plc Purchase of shares and PDMR notification (2947H)

TIDMCLIN

RNS Number : 2947H

Clinigen Group plc

24 March 2020

24 March 2020

Purchase of shares and PDMR notification

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 23 March 2020, two directors and one of the senior management team purchased ordinary shares of GBP0.01p each in the Group. Shaun Chilton bought 10,000 shares, Nick Keher 6,200 shares and David Bryant 4,763 shares.

Shaun Chilton, Group Chief Executive Officer, said:

"Our share purchases are a strong endorsement of our strategy and underlie our belief in the Company and its prospects.

"We are the world experts in providing access to medicines across borders and we are working hard to support Hospital Pharmacists and Physicians across the US, EU and AAA region to help their patients in the current Coronavirus situation.

"We are confident of the continuing demand for our Clinical and Unlicensed Medicines services, and for our portfolio of hospital oncology and anti-infective medicines."

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.

-Ends-

Contact Details

 
 Clinigen Group plc                             Tel: [phone] 
                                                 010 
 Shaun Chilton, Group Chief Executive Officer 
  Nick Keher, Group Chief Financial Officer 
  Matt Parrish, Head of Investor Relations 
 
 Numis Securities Limited - Nominated Adviser   Tel: [phone] 
  & Joint Broker 
 James Black / Freddie Barnfield 
 RBC Capital Markets - Joint Broker             Tel: [phone] 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                            Tel: [phone] 
 Adrian Duffield / Melanie Toyne-Sewell 
  / Phillip Marriage                            Email: [e-mail] 
 

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

For more information on Clinigen, please visit www.clinigengroup.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
 a)   Name                   Shaun Chilton 
     ---------------------  ------------------------------------ 
 2    Reason for the notification 
     ----------------------------------------------------------- 
 a)   Position/status        Chief Executive Officer 
     ---------------------  ------------------------------------ 
 b)   Initial notification   Initial Notification 
       /Amendment 
     ---------------------  ------------------------------------ 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
     ----------------------------------------------------------- 
 a)   Name                   Clinigen Group plc 
     ---------------------  ------------------------------------ 
 b)   Legal Entity           213800OBIKGI2JYYS227 
       Identifier 
     ---------------------  ------------------------------------ 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------- 
 a)   Description            Ordinary shares of 0.1 pence each 
       of the financial       GB00B89J2419 
       instrument, 
       type of instrument 
       Identification 
       code 
     ---------------------  ------------------------------------ 
 b)   Nature of the          Purchase of shares 
       transaction 
     ---------------------  ------------------------------------ 
 c)   Currency               GBP 
     ---------------------  ------------------------------------ 
 d)   Price(s) and                Price(s)          Volume(s) 
       volume(s) 
     ---------------------  -------------------  --------------- 
                              415.5p per share    10,000 shares 
     ---------------------  -------------------  --------------- 
 
 e)   Aggregated              10,000 shares 
       information             415.5p 
       - Aggregated            GBP41,550 
       volume 
       - Price 
       - Aggregated 
       total 
     ---------------------  ------------------------------------ 
 f)   Date of the            23 March 2020 
       transaction 
     ---------------------  ------------------------------------ 
 g)   Place of the           London Stock Exchange, AIM 
       transaction 
     ---------------------  ------------------------------------ 
 
 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
 a)   Name                   Nick Keher 
     ---------------------  ------------------------------------ 
 2    Reason for the notification 
     ----------------------------------------------------------- 
 a)   Position/status        Chief Financial Officer 
     ---------------------  ------------------------------------ 
 b)   Initial notification   Initial Notification 
       /Amendment 
     ---------------------  ------------------------------------ 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
     ----------------------------------------------------------- 
 a)   Name                   Clinigen Group plc 
     ---------------------  ------------------------------------ 
 b)   Legal Entity           213800OBIKGI2JYYS227 
       Identifier 
     ---------------------  ------------------------------------ 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------- 
 a)   Description            Ordinary shares of 0.1 pence each 
       of the financial       GB00B89J2419 
       instrument, 
       type of instrument 
       Identification 
       code 
     ---------------------  ------------------------------------ 
 b)   Nature of the          Purchase of shares 
       transaction 
     ---------------------  ------------------------------------ 
 c)   Currency               GBP 
     ---------------------  ------------------------------------ 
 d)   Price(s) and                Price(s)          Volume(s) 
       volume(s) 
     ---------------------  -------------------  --------------- 
                               400p per share      6,200 shares 
     ---------------------  -------------------  --------------- 
 
 e)   Aggregated              6,200 shares 
       information             400p 
       - Aggregated            GBP24,800 
       volume 
       - Price 
       - Aggregated 
       total 
     ---------------------  ------------------------------------ 
 f)   Date of the            23 March 2020 
       transaction 
     ---------------------  ------------------------------------ 
 g)   Place of the           London Stock Exchange, AIM 
       transaction 
     ---------------------  ------------------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEAFDDAAXEEAA

(END) Dow Jones Newswires

March 24, 2020 03:00 ET (07:00 GMT)